title: Antithrombotic therapy. Rationale and application.
abstract: Arterial thrombosis and venous thrombosis differ in pathogenesis, morphology, and response to antithrombotic therapy. Antiplatelet therapy usually is aimed at arterial thrombi, in whose formation platelet-mediated reactions predominate, while anticoagulant therapy is effective against venous thrombi, in whose formation coagulation predominates.
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001158:Arteries / Q000293:injuries; D001161:Arteriosclerosis / Q000209:etiology; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000096:biosynthesis; D004176:Dipyridamole / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000209:etiology; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014680:Veins / Q000293:injuries; D014859:Warfarin / Q000378:metabolism
chemical_list: D000925:Anticoagulants; D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents; D014859:Warfarin; D004176:Dipyridamole; D014568:Urokinase-Type Plasminogen Activator; D001241:Aspirin; D013442:Sulfinpyrazone